Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
about
Atypical femoral fracture risk in patients treated with bisphosphonates.Association between alendronate and atypical femur fractures: a meta-analysis.Rethinking the Appraisal and Approval of Drugs for Fracture PreventionBisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Bisphosphonates for steroid-induced osteoporosis.Current perspectives on bisphosphonate treatment in Paget's disease of bone.Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.Questioning the association between bisphosphonates and atypical femoral fracturesMechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjectsAtypical femoral fractures and bisphosphonate use: current evidence and clinical implicationsOsteoporosis: the emperor has no clothesAre women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures.A Critical Analysis of Claims and Their Authenticity in Indian Drug Promotional Advertisements.The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).Risk factors for subtrochanteric and diaphyseal fractures: the study of osteoporotic fracturesAtypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.Oral bisphosphonates may not decrease hip fracture risk in elderly Spanish women: a nested case-control study.Understanding the pathogenesis of hip fracture in the elderly, osteoporotic theory is not reflected in the outcome of prevention programmesAtypical femoral fracturesBisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study.Are race and sex associated with the occurrence of atypical femoral fractures?Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies.Long-term Bisphosphonate Therapy-induced Periprosthetic Femoral Stress Fracture in a Sliding Hip Screw Implant: A Unique Case Report.Bisphosphonates and atypical subtrochanteric fractures of the femur.Current and future treatment options in osteoporosis.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies.Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.Disentangling the emerging evidence around atypical fractures.Burden of bisphosphonate-associated femoral fractures.Safety concerns with the long-term management of osteoporosis.Epidemiology of proximal femoral fractures in South Korea.Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review.Rheumatoid arthritis: a case for personalized health care?Review: epidemiology and pathophysiology of atypical femur fractures.Identifying atypical femoral fractures--a retrospective review.Increased risk for atypical fractures associated with bisphosphonate use.Risks and Benefits of Bisphosphonate Therapies.Real-Life and RCT Participants: Alendronate Users Versus FITs' Trial Eligibility Criterion.
P2860
Q33582253-F328A889-A9ED-4CB5-8F5A-61CE63529634Q33596535-22B12D02-A27A-46BC-A5E8-3BB499FFB952Q33679213-D91E5DF6-B157-4658-842C-40722002AF54Q33715141-BCB977C0-59C2-409A-8C45-5807A856E266Q34542004-623806A5-2744-4CD4-8B2D-E9D3C53CEF59Q34566340-B30E2C18-1A93-4179-91F8-0852CF833583Q34626680-781D8603-7460-42A2-A86D-23AD6BD3B055Q34899110-ADB960F9-A5D1-4BBD-AB90-FF01017F9696Q35566438-91905662-3656-4166-A710-F0CA8EB18D56Q35780856-A67E03B9-3310-4D7B-840A-F82E9CA48F65Q35835844-A54A10D1-6A40-41BD-81A6-3D9188E75E31Q36069758-27D47BDD-97D5-4363-BDE4-235AD3E63A4BQ36112657-023125AD-2D1E-4653-817B-12F035B69723Q36190027-C2EAD1E4-9872-42BE-9A55-C54697FDB456Q36589370-32C93979-C597-4D51-8852-5B372A9614A1Q36633388-431EC5CD-82D1-4393-9D37-6D6695D2BA4FQ36649749-07B3674A-E877-4EF3-A974-43C61D922243Q36799635-F979F357-CACB-4EA6-B716-CEAD6C6FA8BAQ37008039-C587F9EC-2DAD-4670-91D4-57CD78F7C818Q37018032-B63971DC-DC73-482F-B379-9F7C2F6DC88EQ37046213-1943CC23-BDD3-4ACD-8753-59DA93C4C4A7Q37563703-B421672F-EC77-4C54-A0B4-FC085AF2199EQ37587913-2D0E57C8-EE6C-44E5-87D0-0419CDDA4A98Q37620384-987E3CEC-3F77-4D5A-8314-D855F002BF23Q37733851-547D6111-57B9-4B09-A2CB-7FF83314A389Q37843715-080BCCB6-563B-45F3-9926-7815AD2D3B55Q37866764-87D936B1-1DFC-4E06-B8E0-BC75BDAA0D2EQ37918967-315601B5-871D-4634-9029-8B01996752A7Q37945476-B6818F03-9121-43D9-BDEF-63B83FA207FCQ37987492-389D7703-8151-4466-A34A-C24E90B43705Q38065319-54503F2B-2AC2-4130-84E1-D14887BDAC87Q38101363-1D215981-FD4E-4377-A542-7BC9B790111BQ38154824-B8B3D9A6-0910-4027-8C4C-3FB92F5AB943Q38164436-AFB6BDCA-2A28-43FD-A5BE-AA6D238DD0B6Q38182471-6F18ADE1-7E22-4C44-B9F6-E94BD447690DQ38187901-F6701CB8-01C0-451A-BB96-E19167731EE2Q38248253-AECC08BC-A395-45D1-95BE-DAF5A7C24074Q38407671-E00C2F0E-08C5-4891-BE74-8BDD803E937FQ38533828-523551E8-F14B-49B1-99A1-F2F9FE41C4C7Q39835356-EC852D5F-C928-4F61-9985-F382DEB0241E
P2860
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cumulative alendronate dose an ...... ased national cohort analysis.
@ast
Cumulative alendronate dose an ...... ased national cohort analysis.
@en
Cumulative alendronate dose an ...... ased national cohort analysis.
@nl
type
label
Cumulative alendronate dose an ...... ased national cohort analysis.
@ast
Cumulative alendronate dose an ...... ased national cohort analysis.
@en
Cumulative alendronate dose an ...... ased national cohort analysis.
@nl
prefLabel
Cumulative alendronate dose an ...... ased national cohort analysis.
@ast
Cumulative alendronate dose an ...... ased national cohort analysis.
@en
Cumulative alendronate dose an ...... ased national cohort analysis.
@nl
P2093
P2860
P356
P1476
Cumulative alendronate dose an ...... ased national cohort analysis.
@en
P2093
Bo Abrahamsen
Richard Eastell
P2860
P304
P356
10.1210/JC.2010-1571
P407
P577
2010-09-15T00:00:00Z